Login to Your Account



Chipscreen's Chidamide Hits Endpoint in Aggressive PTCL

By Larry Schuster
Contributing Writer

Friday, May 24, 2013
SHANGHAI, China – Chipscreen Biosciences Ltd., of Shenzhen, China, reported encouraging Phase II trial results for its Chidamide (formerly HBI-8000) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who had failed at least one prior systemic therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription